-
Zuckerberg skewered again on screen in 'The Social Reckoning'
-
Big guns back for Australia's Rugby League World Cup defence
-
Fiji urges 'just' climate transition, financing at pre-COP gathering
-
Braves rock Dodgers to level series, Brewers win thriller
-
Thailand's Jeeno overcomes late wobble to win Lotte Championship
-
Most Asia stocks rally as 'Goldilocks' jobs data ease rate fears
-
Brazil heads to run-off as Bolsonaro pulls off shock first place finish over Lula
-
Sunken Silk Road city reveals Central Asia's lost history
-
EU, China to hold Beijing talks to avert trade war
-
Three years on, Israeli rescuer cannot escape October 7
-
Bolsonaro edges past Lula as nail-biter Brazil vote goes to a run-off
-
Research into weight-loss drugs tipped for Nobel as award week opens
-
Rubio visits Iceland as US boosts Arctic presence
-
US Supreme Court hears bid to shut the door on climate suits
-
Bolsonaro leads Lula as nail-biter Brazil vote goes to a run-off
-
Chourio walk-off single lifts Brewers over Padres
-
Patriots inflict first Bills defeat as Chiefs keep winning
-
Fulcrum Metals PLC Announces Pilot site & Pilot Technology Agreement Secured
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 05
-
Flavio Bolsonaro leads Lula in near-done Brazil vote count
-
Pacific nations take centre stage at 'pre-COP' climate summit
-
Flavio Bolsonaro leads Lula in partial Brazil poll results
-
Ronaldo can return to Portugal team if he wants: coach Jesus
-
Titan FX Launches Second “Dream Beyond Borders 2.0” Brand Commercial Featuring Keisuke Honda
-
Portugal move into Nations League knockout stage, Germany held
-
Patriots inflict first Bills defeat as Rams surge late
-
Ronaldo-less Portugal beat Norway to reach Nations League quarters
-
Brazil's Indigenous back Lula as El Nino fuels forest fires
-
Bosnian Serb strongman claims election win, thanks Trump and Putin
-
Brazil braces for results of election battle between Lula and Bolsonaro
-
Israel wear black armbands in Ireland tie over Hamas attack
-
Indians protest election chief ahead of top court hearing
-
'I fear it could drag on': anxiety takes hold in Ethiopian city wrested from rebels
-
'Verity' kills, Cruise bombs in N. American movie theaters
-
Brazil's Lula and Flavio Bolsonaro face off in knife-edge election
-
Colts top Commanders in NFL London game
-
UK Green party adopts 'Zionism is racism' policy
-
Hundreds of schools to shut Monday as student protests rock France
-
Rio favela residents vote with little hope
-
Three previous two-time Arc de Triomphe winners
-
Evenepoel puts worlds 'disappointment' to bed with European crown
-
'Champion' Daryz wins second successive Arc in fine style
-
Two-time winning Arc trainer Rouget bows out in emotional farewell
-
Daryz wins second successive Prix de l'Arc de Triomphe
-
Battling Djokovic stuns top seed Zverev at China Open
-
England's seven-goal spree sends message to Euro rivals: Kane
-
Spy chief Clayton, the Trump loyalist tech bosses trust on AI
-
Trump confirms national intelligence chief as new AI czar
-
UK's Glastonbury festival tickets sell out in 45 minutes
-
Up to 500 French schools to be totally or partly closed Monday: minister
Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
A.Jones--AMWN